Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma

Chinese Journal of Pathology

Volumn 41, Issue 6, 2012, Pages 366-370

  Yao, Xiao Xiang ^a   Wang, Jin Fen ^a   Wang, Yue Hua ^a   Gao, Ning ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Diffuse; Immunophenotyping; Large b cell; Lymphoma; Prognosis

Indexed keywords

INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR-4; MEMBRANE METALLOENDOPEPTIDASE; MICRORNA; MIRN223 MICRORNA, HUMAN; PROTEIN BCL 6; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLASSIFICATION; FEMALE; FOLLOW UP; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GERMINAL CENTER; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; NEPRILYSIN; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-6; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863195168     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.06.002     Document Type: Article

References (23)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon; IARC Press, 2008:233-237.
2. Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med, 2008, 132(1): 118-124.
3. Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol, 2009, 22(4): 555.
4. Lu H, Buchan RJ, Cook SA. MicroRNA-223 regulates Clut4 expression and cardiomyocyte glucose metabolism. Cardiovasc Res, 2010, 86 (3)-.410420.
5. Imig J, Motsch N, Zhu JY, et al. MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res,2011, 39 (5): 1880-1893.
6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103 (1) : 275-282. (Pubitemid 38029949)
7. Li S, Li Z, Guo F, et al. miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci, 2011,18: 24.
8. Schmittgen TD, Lee EJ, Jiang J, et al. Real-time PCR quantification of precursor and mature microRNA. Methods, 2008, 44(1): 31-38. (Pubitemid 350297984)
9. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 2008, 14 (11): 2348-2360.
10. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res, 2011,17 (12) : 41254135.
11. van lmhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor risk diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24(25): 4135-4142.
12. Nyman H, Adde M, Karjalainen-Lindsberg ML,et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 2007, 109(11): 49304935.
13. Wilson WH, Dunleavy K, Pitlaluga S, et al. Phase II study of dose-adjusted EPOCH and riluximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol, 2008, 26(16): 2717-2724.
14. Chang CC, McClinlock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 2004,28(4): 464470.
15. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bel-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 2006,208(5): 714-723.
16. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like (GCB) and activated B cell-like subtypes of diffuse large B cell Iymphoma. Int J Cancer, 2007, 121 (5):1156-1161. (Pubitemid 47101656)
17. Jung I, Aguiar RC. MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol, 2009,144 (1) 138-140.
18. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood, 2009, 113 (16) :3754-3764.
19. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res, 2011,17(12): 41254135.
20. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum; a novel class of biomarkers for diagnosis of cancer and other disease. Cell Res, 2008, 18(10): 997-1006.
21. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Nalt Acad Sei USA, 2006,103(7): 2257-2261. (Pubitemid 43271657)
22. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 2007,25(5): 387-392. (Pubitemid 47362758)
23. Fehniger TA, Wylie T, Germino E, et al. Next-generation sequencing identifies the natural killer cell microRNA transcription. Genome Res, 2010, 20 (11) : 1590-1604.